MichaelMannstadtMD
Endocrinology • Boston, MAOsteoporosis & Bone Metabolism Medicine, Parathyroid
Chief, Endocrine Unit, Massachusetts General Hospital Associate Professor of Medicine, Harvard Medical School
Dr. Mannstadt is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
55 Fruit St
Wang ACC 730a Endocrine Associates
Boston, MA 02114Phone+1 617-726-8720Fax+1 617-724-2718
Summary
- I am a board certified endocrinologist specializing on diseases of bone and mineral metabolism. My clinical interests include hypoparathyroidism, hyperparathyroidism, hypocalcemia, hypercalcemia, hyperphosphatemia, hypophosphatemia, genetic bone diseases, Fibrous dysplasia, McCune-Albright syndrome and osteoporosis.
Education & Training
Massachusetts General HospitalFellowship, Endocrinology, Diabetes, and Metabolism, 2004 - 2007- Massachusetts General HospitalChief Residency, Internal Medicine, 2005 - 2006
- Massachusetts General HospitalResidency, Internal Medicine, 2001 - 2004
Friedrich-Schiller-Universität JenaClass of 1991
Certifications & Licensure
MA State Medical License 2003 - 2026- American Board of Internal Medicine Endocrinology, Diabetes and Metabolism
Clinical Trials
- A Open-label Study Investigating the Safety and Tolerability of NPSP558, a Recombinant Human Parathyroid Hormone (rhPTH [1-84]), for the Treatment of Adults With Hypoparathyroidism - A Clinical Extension Study (RACE) Start of enrollment: 2011 Apr 06
- A Registry for Participants With Chronic Hypoparathyroidism Start of enrollment: 2013 Jul 30
- A Clinical Study Investigating the Safety, Tolerability, PK and PD of PCO371 in Patients With Hypoparathyroidism Start of enrollment: 2020 Jul 23
- Join now to see all
Publications & Presentations
PubMed
- 119 citationsEvaluation and Management of Primary Hyperparathyroidism: Summary Statement and Guidelines from the Fifth International Workshop.John P Bilezikian, Aliya A Khan, Shonni J Silverberg, Ghada El-Hajj Fuleihan, Claudio Marcocci
Journal of Bone and Mineral Research. 2022-11-01 - 10 citationsRapid genomic changes by mineralotropic hormones and kinase SIK inhibition drive coordinated renal Cyp27b1 and Cyp24a1 expression via CREB modules.Mark B Meyer, Nancy A Benkusky, Seong Min Lee, Sung-Hee Yoon, Michael Mannstadt
The Journal of Biological Chemistry. 2022-11-01 - 12 citationsManagement of Hypoparathyroidism.Aliya A Khan, Gordon Guyatt, Dalal S Ali, John P Bilezikian, Michael T Collins
Journal of Bone and Mineral Research. 2022-12-01
Journal Articles
- A New Multi-System Disorder Caused by the Gαs Mutation p.F376VMichael Mannstadt, MD, The Journal of Clinical Endocrinology and Metabolism
Lectures
- Meeting the Needs of Patients, Not LDL-C Goals: The Role of PCSK9 InhibitorENDO 2019 - New Orleans, LA - 3/25/2019
- Challenges in Treating Hypoparathyroid Patients (Repeat)ENDO 2019 - New Orleans, LA - 3/24/2019
- Challenges in Treating Hypoparathyroid PatientsENDO 2019 - New Orleans, LA - 3/24/2019
- Join now to see all
Press Mentions
Recall of Takeda's Natpara Leaves Patients in Health LimboSeptember 16th, 2019
Understanding Healthy Bone Growth in Childhood to Improve Long-Term Quality of LifeApril 29th, 2014- Hormone Level May Reflect Mortality Risk Among Dialysis PatientsAugust 6th, 2008
- Join now to see all
Grant Support
- R01NIH NIDDKPresent
Professional Memberships
- Member
- American Society of Bone and Mineral ResearchMember
External Links
- Research Homepagehttp://www.massgeneral.org/research/researchlab.aspx?id=1256
- Lab Homepagehttps://mannstadt.mgh.harvard.edu
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
